title: [Radical surgery and intensive chemotherapy are necessary for successful treatment of osteosarcoma].
abstract: BACKGROUND
  We evaluated the therapeutic results in 44 patients (17 girls and 27 boys) with osteosarcoma from 1997 to 2006.Their average age was 12.8 years (2.5-20.2). 41 patients had localised disease and 3 had primary metastases.
  
  
  METHODS
  We treated our 44 patients using CCG 7921 POG 9351 INT 0133, the therapeutic protocol of the North American cooperative Children's Oncology Group.The median of the follow up was 5.5 years (2-11 years).
  
  
  RESULTS
  40 patients went into complete remission. 19 patients suffered relapses. Of these, 17 patients died - 15 progressed, 1 died due to treatment-related toxicity, 1 died due to secondary acute myeloid leukaemia. As a whole, the patients had a 5-year overall survival rate (OS) of 58.4% and a 5-year event free survival rate (EFS) of 46.7%. The patients with localised extremity osteosarcoma (n = 40) had a 5-year EFS rate of 51%. The patients with good histological response (n = 22) had a 5-year EFS rate of 63.6%, while patients with poor histological response (n = 18) achieved a 5-year EFS rate of 30.5% (p = 0.009).
  
  
  CONCLUSIONS
  The results of treatment of patients with localised extremity osteosarcoma and patients with good histological response to preoperative treatment were very good. The prognosis of patients with axial localisation and metastatic involvement was poor.
authors.affiliation: Klinika detské hematologie a onkologie 2. LF UK a FN Motol, Praha. jarmila.kruseova@fnmotol.cz
authors.forename: J
authors.initials: J
authors.lastname: Kruseová
authors.forename: H
authors.initials: H
authors.lastname: Mottl
authors.forename: R
authors.initials: R
authors.lastname: Kodet
authors.forename: J
authors.initials: J
authors.lastname: Mrácek
authors.forename: Z ml
authors.initials: Zm
authors.lastname: Matejovský
authors.forename: J
authors.initials: J
authors.lastname: Schovanec
authors.forename: J
authors.initials: J
authors.lastname: Snajdauf
authors.forename: M
authors.initials: M
authors.lastname: Rygl
authors.forename: I
authors.initials: I
authors.lastname: Lisková
authors.forename: E
authors.initials: E
authors.lastname: Kabítková
authors.forename: J
authors.initials: J
authors.lastname: Malis
authors.forename: D
authors.initials: D
authors.lastname: Sumerauer
authors.forename: E
authors.initials: E
authors.lastname: Drahokoupilová
authors.forename: M
authors.initials: M
authors.lastname: Ganevová
authors.forename: V
authors.initials: V
authors.lastname: Smelhaus
authors.forename: J
authors.initials: J
authors.lastname: Starý
mesh_terms: D000293:Adolescent; D001859:Bone Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D012516:Osteosarcoma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D055815:Young Adult